Disease Information

General Information of the Disease (ID: DIS00271)

• Name: Cerebral artery disease
• ICD: ICD-11: 8B26

Type(s) of Resistant Mechanism of This Disease

  IDUE: Irregularity in Drug Uptake and Drug Efflux

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Drug

Approved Drug(s) 1 drug(s) in total

Cilostazol

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Irregularity in Drug Uptake and Drug Efflux (IDUE)

Key Molecule: ATP-binding cassette sub-family C4 (ABCC4) [1]

• Sensitive Disease: Cerebral artery disease [ICD-11: 8B26.2]
• Molecule Alteration: Function; Inhibition
• Sensitive Drug: Cilostazol
• Experimental Note: Identified from the Human Clinical Data
• Cell Pathway Regulation: JAK2 signaling pathway; Activation; hsa04917
• Cell Pathway Regulation: STAT3 signaling pathway; Activation; hsa04550
• Mechanism Description: Cilostazol has been implicated in a number of other basic pathways including the inhibition of adenosine reuptake, the inhibition of multidrug resistance protein 4, among others. Mouse models of myocardial ischemia reperfusion have associated cilostazol with attenuation of multiple inflammatory markers through activation of PPAR gamma, JAK2, and STAT3 pathways

Key Molecule: ATP-binding cassette sub-family C4 (ABCC4) [1]

• Sensitive Disease: Cerebral artery disease [ICD-11: 8B26.2]
• Molecule Alteration: Function; Inhibition
• Sensitive Drug: Cilostazol
• Experimental Note: Identified from the Human Clinical Data
• Cell Pathway Regulation: JAK2 signaling pathway; Activation; hsa04917
• Cell Pathway Regulation: STAT3 signaling pathway; Activation; hsa04550
• Mechanism Description: Cilostazol has been implicated in a number of other basic pathways including the inhibition of adenosine reuptake, the inhibition of multidrug resistance protein 4, among others. Mouse models of myocardial ischemia reperfusion have associated cilostazol with attenuation of multiple inflammatory markers through activation of PPAR gamma, JAK2, and STAT3 pathways

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: Phosphodiesterase III (PDE) [1]

• Sensitive Disease: Cerebral artery disease [ICD-11: 8B26.2]
• Molecule Alteration: Function; Inhibition
• Sensitive Drug: Cilostazol
• Experimental Note: Identified from the Human Clinical Data
• Cell Pathway Regulation: JAK2 signaling pathway; Activation; hsa04917
• Cell Pathway Regulation: STAT3 signaling pathway; Activation; hsa04550
• Mechanism Description: Cilostazol has been implicated in a number of other basic pathways including the inhibition of adenosine reuptake, the inhibition of multidrug resistance protein 4, among others. Mouse models of myocardial ischemia reperfusion have associated cilostazol with attenuation of multiple inflammatory markers through activation of PPAR gamma, JAK2, and STAT3 pathways

Key Molecule: Phosphodiesterase III (PDE) [1]

• Sensitive Disease: Cerebral artery disease [ICD-11: 8B26.2]
• Molecule Alteration: Function; Inhibition
• Sensitive Drug: Cilostazol
• Experimental Note: Identified from the Human Clinical Data
• Cell Pathway Regulation: JAK2 signaling pathway; Activation; hsa04917
• Cell Pathway Regulation: STAT3 signaling pathway; Activation; hsa04550
• Mechanism Description: Cilostazol has been implicated in a number of other basic pathways including the inhibition of adenosine reuptake, the inhibition of multidrug resistance protein 4, among others. Mouse models of myocardial ischemia reperfusion have associated cilostazol with attenuation of multiple inflammatory markers through activation of PPAR gamma, JAK2, and STAT3 pathways

References

• Ref 1: Cilostazol: a Review of Basic Mechanisms and Clinical Uses .Cardiovasc Drugs Ther. 2021 Apr 16. doi: 10.1007/s10557-021-07187-x. Online ahead of print. 10.1007/s10557-021-07187-x